(Q42945863)

11 November 2017

Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease (English)

1 reference

autosomal dominant polycystic kidney disease

11 November 2017

0 references

sirolimus

1 reference

autosomal dominant polycystic kidney

inferred from title

1 reference

Iram Zafar

1

1 reference

11 November 2017

Kameswaran Ravichandran

2

1 reference

11 November 2017

Franck A Belibi

3

1 reference

11 November 2017

R Brian Doctor

4

1 reference

11 November 2017

Charles L Edelstein

5

1 reference

11 November 2017

language of work or name

English

0 references

publication date

4 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

78

1 reference

11 November 2017

8

1 reference

11 November 2017

754-761

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2010.250

11 November 2017

0 references

cites work

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Emerging evidence of a link between the polycystins and the mTOR pathways

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Polycystic kidney disease--a tale of calcium channels and the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent cell cell mechanical adhesion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

TOR signaling in growth and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Cardiac defects and renal failure in mice with targeted mutations in Pkd2

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

The pathogenesis of autosomal dominant polycystic kidney disease: an update

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

c-myc as an inducer of polycystic kidney disease in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

The effect of rapamycin on kidney function in the Sprague-Dawley rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Functional and histopathologic effects of rapamycin on mouse kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

PKD1 interacts with PKD2 through a probable coiled-coil domain

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Polycystin-1 and -2 Dosage Regulates Pressure Sensing

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

The TSC1-TSC2 complex is required for proper activation of mTOR complex 2

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Somatic inactivation of Pkd2 results in polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Rapamycin-sensitive induction of eukaryotic initiation factor 4F in regenerating mouse liver

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Downregulation of the calpain inhibitor protein calpastatin by caspases during renal ischemia-reperfusion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.250

7 January 2021

Identifiers

DOI

10.1038/KI.2010.250

1 reference

11 November 2017

1 reference